|
|
|
|
Researchers Use Fluidigm Nanofluidic Digital PCR Array to Quantify Mutations in Lung Cancer Gene
Researchers from Case Western Reserve University and Fluidigm have published a paper demonstrating how Fluidigm's nanofluidic digital PCR platform can detect and quantify EGFR mutations at the single-molecule level from lung tumors, including formalin-fixed,...
|
|
|
Targeting leukemia cells gene addiction presents new strategy for treatment
Buy Maxalt Without a Prescription Buy no Prescription Strattera Order Tamiflu no Prescription Online Buy Medrol Without a Prescription Buy Naltrexone Without a Prescription Buy no Prescription Antabuse Online Buy Boniva no Prescription Buy Propecia Without a...
|
|
|
Don't Wait For Roche, Take The Money And Run
Swiss drugmaker is unlikely to top OSI Pharma's $3 billion hostile bid from Japan's Astellas.Shares of OSI Pharmaceuticals inched higher Tuesday as investors pondered whether Japanese drugmaker Astellas Pharma will be succesfful with its unsolicited takeover...
|
|
|
Single-agent gefitinib doubles time-to-progression in non-small-cell lung cancer patients with EGF
The seminal IPASS study by Tony Mok, MD, and colleagues demonstrated moderate efficacy for gefitinib (Iressa) in advanced nonsmallcell lung cancer patients, most notably in patients with predictive factors, including adenocarcinoma histology, no history...
|
|
|
Table: Drugs with Pharmacogenomic Tests
The Gene Factor Patients with a mutation in the CYP2D6 gene are at risk of suffering serious liver damage.Drug Clopidogrel (Plavix) Purpose Prevents heart attacks by inhibiting blood clots The Gene Factor A variation of the CYP2C19 gene interferes with the...
|
|
|
Iressa Improves Survival in Patients with NSCLC Harboring EGFR Mutations
Patients with nonsmall cell lung cancer (NSCLC) who have a mutation of the epidermal growth factor receptor (EGFR) experienced a better progression-free survival when treated with Iressa (gefitinib) rather than the standard doublet therapy consisting of...
|
|
|
Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy
Lee DH et al.The ISTANA (IRESSA as Second-line Therapy in Advanced NSCLCKoreA) study compared gefitinib with docetaxel in patients with advanced or metastatic nonsmall cell lung carcinoma (NSCLC) pretreated with platinum-based chemotherapy.
|
|
|
Insulin study could lead to new dosage devices
Buy Maxalt Without a Prescription Buy no Prescription Strattera Order Tamiflu no Prescription Online Buy Medrol Without a Prescription Buy Naltrexone Without a Prescription Buy no Prescription Antabuse Online Buy Boniva no Prescription Buy Propecia Without a...
|
|
|
Kidney cancer proves more complicated than thought
* New genetic mutations linked to kidney cancer * Research underlines need for tailored treatments LONDON (Reuters) - The more scientists look, the more complex cancer seems to become.British scientists said on Wednesday they had found a batch of new gene...
|
|
|
Lung cancer: New drug shows promise in lab mice
PARIS (AFP) A new category of drug brakes the growth of treatment-resistant lung cancer among lab mice, according to a study published on Thursday in the science journal Nature.The new type could add powerfully to a small family of drugs called epidermal...
|
|
|
Surveyed European Oncologists Cite Cost Most Frequently as the Factor Preventing Their Use of Avastin for Non-
See more news releases in: Publishing & Information Services, Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Surveys, Polls and Research Relative to Other European Markets, Cost-Sharing Schemes for Targeted Therapies are Much...
|
